Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07724223 Cetuximab Metastatic Colorectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07724223 clinical trial report covering Cetuximab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07726433 Fosrolapitant/Palonosetron Nausea Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07726433 clinical trial report covering Fosrolapitant/Palonosetron, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600128749 Cyclosporine Anemia, Aplastic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
ChiCTR2600128749 clinical trial report covering Cyclosporine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07726342 SMP-656 Locally advanced breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07726342 clinical trial report covering SMP-656, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07725497 Luspatercept-AAMT Anemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07725497 clinical trial report covering Luspatercept-AAMT, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600128718 Carboplatin Squamous cell carcinoma of the oral cavity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
ChiCTR2600128718 clinical trial report covering Carboplatin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07725939 Galvokimig Bronchitis, Chronic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07725939 clinical trial report covering Galvokimig, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600128734 Trastuzumab biosimilar (Chia-tai Tianqing) Advanced Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
ChiCTR2600128734 clinical trial report covering Trastuzumab biosimilar (Chia-tai Tianqing), Phase 2, endpoints, sponsor, geography, readout timing and deve
Latest Hotspot
8 min read
ChiCTR2600128773 Toripalimab HER2-Expressing Non-Muscle Invasive Bladder Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
ChiCTR2600128773 clinical trial report covering Toripalimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600128788 Toripalimab HER2 Positive Muscle Invasive Bladder Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
ChiCTR2600128788 clinical trial report covering Toripalimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262854 Recombinant Zoster Vaccine (CHO cell) (Jianda Biomedical) Herpes Zoster Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20262854 clinical trial report covering Recombinant Zoster Vaccine (CHO cell) (Jianda Biomedical), Phase 2, endpoints, sponsor, geography, readout timin
Latest Hotspot
8 min read
CTR20262867 Xiaoer Liuwei Eczema gel Eczema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20262867 clinical trial report covering Xiaoer Liuwei Eczema gel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.